Drugmaker Cipla to set up manufacturing plant in Iran

Written By Unknown on Selasa, 07 Oktober 2014 | 23.25

The Indian drugmaker, which made headlines in 2001 by making antiretroviral medicines to treat AIDS in Africa for under USD 1 per day, gets more than half its revenue from markets outside India, including the United States and Europe.

Generic drugmaker  Cipla has agreed to set up a manufacturing plant in Iran, as part of its strategy to boost its presence in the country's USD 4 billion pharmaceuticals market that is growing at about 13 percent annually.

Cipla, which will own 75 percent stake in the plant being set up in partnership with its local distributor, will invest about USD 36.65 million over three years on areas including machinery and equipment for the facility.

The Indian drugmaker, which made headlines in 2001 by making antiretroviral medicines to treat AIDS in Africa for under USD 1 per day, gets more than half its revenue from markets outside India, including the United States and Europe.

Although the sanctions regime, imposed by the United States and European Union over Tehran's nuclear programme, allows trade in humanitarian goods such as food and medicine, not many Indian drugmakers have significant presence in Iran.

"Cipla has been providing medicines to patients in Iran for several years and believes that Iranian patients cannot be denied to medicines due to sanctions," the company said in a statement to Reuters on Tuesday.

"We have observed a high prevalence of respiratory disorders and cancer cases in Iran. There were also patients suffering with diseases like thalassemia, HIV/AIDS and heart diseases, who have been at a risk due to the impact of sanctions," it said.

Setting up the plant will help in faster registrations of new products and will improve its competitive position, the company said, adding it does not expect any impact on its US and European businesses due to its investments in Iran.

Cipla stock price

On October 07, 2014, Cipla closed at Rs 600.35, down Rs 22.9, or 3.67 percent. The 52-week high of the share was Rs 639.05 and the 52-week low was Rs 366.70.


The company's trailing 12-month (TTM) EPS was at Rs 15.51 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 38.71. The latest book value of the company is Rs 125.69 per share. At current value, the price-to-book value of the company is 4.78.


Anda sedang membaca artikel tentang

Drugmaker Cipla to set up manufacturing plant in Iran

Dengan url

http://gayafashionshow.blogspot.com/2014/10/drugmaker-cipla-to-set-up-manufacturing.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Drugmaker Cipla to set up manufacturing plant in Iran

namun jangan lupa untuk meletakkan link

Drugmaker Cipla to set up manufacturing plant in Iran

sebagai sumbernya

0 komentar:

Posting Komentar

techieblogger.com Techie Blogger Techie Blogger